Belite Bio Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Belite Bio Inc in the fourth quarter 2025?
Belite Bio Inc recorded a cumulative net loss of $-78 million during 12 months ending in the fourth quarter 2025, resulting in a negative return on equity (ROE) of -10.07%.

Within the Major Pharmaceutical Preparations industry 96 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 2955 to 3134.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	428.38 %	428.38 %	428.38 %	428.38 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-78	-36	-36	-36	-36
Return On Equity (TTM)	-10.07 %	-5.88 %	-7.89 %	-11.97 %	-24.79 %
BLTE's Total Ranking	# 3134	# 2955	#	#	#
Equity (TTM) in Millions	770	770	770	770	146
Seq. Equity Change	0 %	0 %	0 %	428.38 %	0 %
Seq. Net Income Change	-	-	-	-	-

Back to BLTE Management Effectiveness >> BLTE's 5 Years Annual ROE >> Compare BLTE ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 97
Sector	# 272
Overall	# 3134

Return On Equity Statistics
High	Average	Low
-10.07 %	-23.28 %	-34.98 %
(Dec 31 2025)		(Dec 31 2023)

News about Belite Bio Inc Return on Equity ROE

Belite Bio Secures FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease,

Belite Bio s Breakthrough in the Treatment of Stargardt DiseaseBelite Bio Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical company, has recently been thrust into the spotlight with the announcement that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its drug candidate, Tinlarebant, for the treatment of Stargardt Disease (STGD1). This designation is significant as it not only accelerates the development and review process for Tinlarebant but also highlights the urgent need for innovative therapies targeting degenerative retinal diseases, which have long suffered from significant unmet medical needs. Stargardt Disease and Tinlarebant Stargardt disease is a genetic eye disorder that affects the retina and leads to progressive vision loss. Despite its serious impact on patients quality of life, there are currently no FDA-approved treatments for STGD1. Tinlarebant, Belite Bio s promising candidate, has been under investigation in the ongoing Phase 3 DRAGON trial. The FDA s decision to grant Breakthrough Therapy Designation is based on positive interim data from this trial, underscoring Tinlarebant’s potential to transform the treatment landscape for STGD1.

Advancing Therapeutics in Retinal Disease The Promise of Tinlarebant and the Challenges Facing Belite Bio

The development of novel therapeutics for retinal diseases represents a significant frontier in pharmaceutical innovation, especially for conditions like Stargardt Disease (STGD1), which currently lacks effective treatment options. Belite Bio, Inc. a clinical-stage biopharmaceutical company based in San Diego, is at the forefront of this endeavor with its recent announcement concerning the DRAGON II clinical trial of Tinlarebant, an oral therapy designed to target the underlying causes of STGD1.Tinlarebant is specifically designed to mitigate the harmful accumulation of vitamin A derivatives, recognized as significant contributors to the pathogenesis of STGD1. This trial s Phase 2/3 segment intends to evaluate the efficacy, safety, and tolerability of this promising treatment in approximately 60 adolescent patients across three countries: the United States, the United Kingdom, and Japan. The initiation of dosing in this trial, as reported on September 10, 2024, marks a crucial step forward in the quest for effective therapies against degenerative retinal diseases.

BLTE Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022
Total Equity in Millions	770	146	90	42	0
Y / Y Equity Change	428.38 %	61.25 %	117.9 %	-	-
Net Income in Millions	-78	-36	-32	-13	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-10.07 %	-24.79 %	-34.98 %	-30.48 %	-

Back to BLTE Management Effectiveness >> BLTE's 5 Years Annual ROE >> Compare BLTE ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BLTE's' Return on Equity at Yahoo Finance
BLTE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BLTE's Competitors
Subscribers only: Roe for Belite Bio Inc's Suppliers
Subscribers only: Return On Equity for BLTE's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector

ROE

Date modified: 2026-07-07T09:35:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.